Eli Lilly wins China approval for first oral GLP-1 weight-loss drug, beating Novo Nordisk
Published 2 d ago2 sourcesEvidence: Reported
Dentists report an increase in patients experiencing oral side effects, termed 'Ozempic teeth', associated with GLP-1 drug use for diabetes and obesity. The condition is emerging as a secondary health consequence of the drugs' growing popularity, though the causal mechanism and prevalence remain unclear. This highlights a potential new public health consideration for the expanding GLP-1 patient population.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 2 d ago2 sourcesEvidence: Reported
Published 12 h ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago6 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported